Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Indoximod [1-methyl-D-tryptophan (D-1MT)] in Patients With Relapsed or Refractory Solid Tumors

NCT00739609 is registered in ClinicalTrials.gov with NewLink Genetics Corporation as lead sponsor.

NCT NCT00739609
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00739609 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Indoximod [1-methyl-D-tryptophan (D-1MT)] in Patients With Relapsed or Refractory Solid Tumors
Lead sponsor
NewLink Genetics Corporation
Phase
Phase 1
Overall status
Terminated
Start date
August 31, 2008
Completion date
October 31, 2012
Enrollment
17 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, lung cancer, melanoma, pancreatic cancer, solid tumors